MedPath

Effect of Alfentanil and Remifentanil on QT Interval

Phase 2
Conditions
QT Prolongation.
Electrocardiogram [ECG][EKG]
R 94.3
Registration Number
IRCT2014020816524N1
Lead Sponsor
Vice Chancellor for Research, Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Patients with physical status class I -II, based on the classification of the American Society of Anesthesiologists (ASA) and the age up to50 years undergoing septoplasty. Exclusion criteria: the use of any effective drug on QT interval in 14 days before surgery (TCA); beta antagonist, anti-arrhythmic, the calcium channel blocker) ; QTc more than 440 m/s; The existence of branches blocks, arrhythmia (preexitation syndrome) ; Structural heart disease.; electrolyte imbalance; hyper or hypothyroid patients 7. Extreme Obesity BMI 30 >; Diabetic neuropathy; Any non- sinus rhythm in EKG; A history of sensitivity to propofol, egg and soy.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
QT interval. Timepoint: Prioperative /Six times. Method of measurement: EKG.
Secondary Outcome Measures
NameTimeMethod
Heart Rate Monitoring. Timepoint: Six Times Perioperative. Method of measurement: EKG.
© Copyright 2025. All Rights Reserved by MedPath